[1] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
|
[2] |
Gan L, Liu Z, Sun C. Obesity linking to hepatocellular carcinoma: A global view[J]. Biochim Biophys Acta Rev Cancer, 2018, 1869(2): 97-102.
|
[3] |
官守涛,唐微,赵杰, 等. 山药多糖对镉致小鼠急性肝损伤的预防作用[J]. 湖北医药学院学报, 2013, 32(2): 115-117.
|
[4] |
石亿心,于莲,翟美芳, 等. 纳米山药多糖对4种肿瘤细胞的作用[J]. 中国现代应用药学, 2016, 33(8): 967-971.
|
[5] |
Longqiu Y, Pengcheng L, Xuejie F, et al. A miRNAs panel promotes the proliferation and invasion of colorectal cancer cells by targeting GABBR1[J]. Cancer Med, 2016, 5(8): 2022-2031.
|
[6] |
Liu H, Cao B, Zhao Y, et al. Upregulated miR-221/222 promotes cell proliferation and invasion and is associated with invasive features in retinoblastoma[J]. Cancer Biomark, 2018, 22(4): 621-629.
|
[7] |
Zhang Z, Li X, Sun W, et al. Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis[J]. Cancer Lett, 2017, 397: 33-42.
|
[8] |
Xue J, Niu YF, Huang J, et al. miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3[J]. Tumour Biol, 2014, 35(12): 12103-12107.
|
[9] |
Wang Y, Bao W, Liu Y, et al. miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1[J]. Cell Death Dis, 2018, 9(5): 447.
|
[10] |
Wu F, Mo Q, Wan X, et al. NEAT1/hsa-mir-98-5p/MAPK6 axis is involved in non-small-cell lung cancer development[J]. J Cell Biochem, 2019, 120(3): 2836-2846.
|
[11] |
Kim J B, Lee S, Kim HR, et al. Transforming growth factor-β decreases side population cells in hepatocellular carcinoma in vitro[J]. Oncol Lett, 2018, 15(6): 8723-8728.
|
[12] |
Meindl-Beinker NM, Matsuzaki K, Dooley S. TGF-β signaling in onset and progression of hepatocellular carcinoma[J]. Dig Dis, 2012, 30(5): 514-523.
|
[13] |
Cui H, Li T, Wang L, et al. Dioscorea bulbifera polysaccharide and cyclophosphamide combination enhances anti-cervical cancer effect and attenuates immunosuppression and oxidative stress in mice[J]. Sci Rep, 2016, 5: 19185.
|
[14] |
Lei Z, Xu G, Wang L, et al. MiR-142-3p represses TGF-β-induced growth inhibition through repression of TGFβR1 in non-small cell lung cancer[J]. Faseb j, 2014, 28(6): 2696-2704.
|
[15] |
Jia P, Wei G, Zhou C, et al. Upregulation of miR-212 inhibits migration and tumorigenicity and inactivates Wnt/β-Catenin signaling in human hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2018, 17: 1533034618765221.
|
[16] |
Zhang Q, Hou X, Evans BJ, et al. LY2157299 monohydrate, a TGF-βR1 inhibitor, suppresses tumor growth and ascites development in ovarian cancer[J]. Cancers (Basel), 2018, 10(8): 260.
|
[17] |
Neuzillet C, Tijeras-Raballand A, Cohen R, et al. Targeting the TGFβ pathway for cancer therapy[J]. Pharmacol Ther, 2015, 147: 22-31.
|
[18] |
Wang ML, Wu DB, Tao YC, et al. The truncated mutant HBsAg expression increases the tumorigenesis of hepatitis B virus by regulating TGF-β/Smad signaling pathway[J]. Virol J, 2018, 15(1): 61.
|
[19] |
Yin S, Fan Y, Zhang H, et al. Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis[J]. Nat Commun, 2016, 7: 11012.
|